HelpLine 1-800-298-2436

New Drug Approved for ALK-Positive NSCLC Patients

Friday, April 28, 2017 - The Food and Drug Administration (FDA) granted accelerated approval to brigatinib (ALUNBRIG tablets) for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

Click here to learn more.